18 slides from Grifols, S.a. Class A's earnings presentation, Oct 31, 2012
Slide 1: Third Quarter 2012 Report
y | THIRD QUARTER 2012 REPORT GRIFOLS
Slide 2: Disclaimer
2 third quarter 2012 report DISCLAIMER The facts and figures contained in this report which do not refer to historical data are “projections and forward-looking statements”. The words and expressions like “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “try to achieve”, “es
Slide 3: Commercial strategy focused on growth in regions with better margins
3 third quarter 2012 report Confirmation in the third quarter of the implementation of Grifols’ CommerCial strateGy foCused on growth in regions with better margins and shorter ColleCtion periods 9.7% quarterly sales’ Growth in north ameriCa at Constant CurrenCy exceeding prior quarter’s growth rate
Slide 4: Profit and loss: main indicators, sales performance
4 third quarter 2012 report 1. profit and loss: main indicators sales performance: pro-forma1 and reported3 results Grifols’ accumulated revenues have risen by 14.4% (7.8% at constant currency, cc) during the first nine months of the year, reaching 1,959.5 million euros to September, compared to 1,7
Slide 5: Sales revenue in the European Union remained stable
5 third quarter 2012 report Sales revenue in the European Union remained stable, representing almost 22% of total sales Grifols’ recurring income in the European Union, excluding Spain, remained stable at around 262 million euros, while revenues in Spain fell by 8.6%1 to 165 million euros. Continuin
Slide 6: Diagnostic and Hospital division sales
6 third quarter 2012 report Diagnostic increased its sales revenue by 16.9% (14.5% cc) to 102.3 million euros, as part of its internationalization drive. Demand continues to rise in markets with dynamic economies in the context of a moderate price recovery. Inmunohematology reagent cards have shown
Slide 7: Margins and profits
7 third quarter 2012 report margins and profits The positive performance of sales, with lower exposure to Europe, and the gradual optimization of yields per liter of plasma (raw material) as a consequence of the improvement and greater flexibility of manufacturing processes, is helping to improve ma
Slide 8: Key indicators for the third quarter of 2012
8 third quarter 2012 report 2. key indicators for the third quarter of 2012 The sales reported by Grifols from July to September 2012 totaled 642.8 million euros and represent an increase of 12.9% (1.6% cc) with respect to the same period of the previous year. By geographic region, North America saw
Slide 9: Third quarter sales by division
9 third quarter 2012 report results obtained from January to September 2012 are more representative. The Bioscience division, with sales revenue of 571.1 million euros, delivered growth of 15.4%, accounting for 88.8% of the group’s total income. The Diagnostic division generated 32.7 million euros,
Slide 10: Key balance sheet items as of September 2012
10 third quarter 2012 report 3. key balance sheet items as of september 2012 Total consolidated assets as of September 2012 amounted to 5,837.3 million euros, compared to 5,807.7 million euros reported in December 2011. Debtor balances have significantly decreased, with average collection terms impr
Slide 11: Analysis by business area: Bioscience division
11 third quarter 2012 report analysis by business area and third quarter highlights bioscience division: 88.5% of income Double digit growth in North America Grifols has consolidated its leading position in the North American market, with high sales volumes in the main plasma derived proteins and th
Slide 12: Diagnostic division highlights
12 third quarter 2012 report diagnostic division: 5.2% of sales New DG Gel® cards dosing line The installation of a new dosing line for gel cards (DG Gel®) in the Barcelona plant has been completed. The new line’s objective is to increase the production speed in order to meet market’s strong demand.
Slide 13: Global strategy for the investigation of Alzheimer's
13 third quarter 2012 report presentation of global strategy for the investigation of alZheimer’s Coinciding with “World Alzheimer’s Day” (21 September), Grifols presented the main research projects that constitute the group’s global Alzheimer’s research strategy, the aim of which is to provide an i
Slide 14: Pro-forma sales
14 third quarter 2012 report 5. pro-forma sales1 2012 pro-forma1 sales by division thousands of euros 9m2012 %sales 9m2011 %sales % var % var CC bioscience 1,734,800 88.5 1,517,388 88.6 14.3 7.2 hospital 74,142 3.8 70,743 4.1 4.8 4.4 diagnostic 102,283 5.2 87,480 5.1 16.9 14.5 raw materials and othe
Slide 15: Reported profit and loss account
15 third quarter 2012 report reported profit and loss account3 thousands of euros 9m2012 9m2011 % var. net revenue 1,959,516 1,205,540 62.5 cost of sales (959,644) (655,062) 46.5 gross profit 999,872 550,478 81.6 % ON SALES 51.0 45.7 r&d (90,369) (58,387) 54.8 sga (399,045) (308,665) 29.3 operating
Slide 16: Balance sheet
16 third quarter 2012 report balance thousands of euros september 2012 december 2011 assets non-current assets 3,915,897 3,878,503 goodwill and other intangible 2,906,566 2,903,408 property, plant & equipment 809,060 775,869 other non-current assets 200,271 199,226 current assets 1,921,424 1,929,215
Slide 17: Cash flow
17 third quarter 2012 report cash flow3 thousands of euros 9m12 9m11 net income 197,343 43,793 depreciation and amortitZation 97,327 59,765 net provisions 1,432 17,781 other adjustments-net 62,957 15,815 changes in inventories 3,391 8,059 changes in trade receivables 28,201 (30,833) changes in trade
Slide 18: Grifols' daily share price vs IBEX 35
18 third quarter 2012 report grifols’ daily share price, class a & class b vs ibex 35 ( base 100, from january 1 to september 30 2012) 2012 Feb Mar Apr May Jun Jul Aug Sep grifols 197,69 grifols b 209,52 ibex 89,99 200 150 100 1 Unaudited pro-forma figures to May 2011, provided for guidance purposes